Thanatop : A novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase IIPOLYCARPOU-SCHWARZ, Maria; MÜLLER, Kerstin; DENGER, Stefanie et al.Cancer research (Baltimore). 2007, Vol 67, Num 9, pp 4451-4458, issn 0008-5472, 8 p.Article

NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo EfficacyDOUGHERTY, Thomas J; NAYAR, Asha; NEWMAN, Joseph V et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 5, pp 2657-2664, issn 0066-4804, 8 p.Article

Targeted Cancer Therapy with a 2-Deoxyglucose―Based Adriamycin ComplexJIE CAO; SISI CUI; SIWEN LI et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 4, pp 1362-1373, issn 0008-5472, 12 p.Article

Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicityLI JING; YINGLIANG WU; JING WU et al.European journal of pharmacology. 2011, Vol 659, Num 2-3, pp 224-232, issn 0014-2999, 9 p.Article

Type IIA topoisomerase inhibition by a new class of antibacterial agentsBAX, Benjamin D; CHAN, Pan F; JIANZHONG HUANG et al.Nature (London). 2010, Vol 466, Num 7309, pp 935-940, issn 0028-0836, 6 p.Article

Formulation and cytotoxicity of doxorubicin loaded in self-assembled bio-polyelectrolyte microshellsXIA TAO; HUA CHEN; SUN, Xue-Jun et al.International journal of pharmaceutics. 2007, Vol 336, Num 2, pp 376-381, issn 0378-5173, 6 p.Article

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 InhibitionTURNER, Joel G; MARCHION, Douglas C; DAWSON, Jana L et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 17, pp 6899-6905, issn 0008-5472, 7 p.Article

Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in VitroTAKAHASHI, Ryan H; BAINS, Onkar S; PFEIFER, Tom A et al.Drug metabolism and disposition. 2008, Vol 36, Num 6, pp 991-994, issn 0090-9556, 4 p.Article

Early and late arrhythmogenic effects of doxorubicinKILICKAP, Saadettin; BARISTA, Ibrahim; AKGUL, Ebru et al.Southern medical journal (Birmingham). 2007, Vol 100, Num 3, pp 262-265, issn 0038-4348, 4 p.Article

Tumor Cells Upregulate Normoxic HIF-1α in Response to DoxorubicinYITING CAO; EBLE, Joseph M; DEWHIRST, Mark W et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 20, pp 6230-6242, issn 0008-5472, 13 p.Article

Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cellsMAMIDIPUDI, Vidya; TAO SHI; BRADY, Helen et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 965-976, issn 0344-5704, 12 p.Article

Cardioprotective roles of aged garlic extract, grape seed proanthocyanidin, and hazelnut on doxorubicin-induced cardiotoxicityDEMIRKAYA, Erkan; AVCI, Aslihan; KESIK, Vural et al.Canadian journal of physiology and pharmacology. 2009, Vol 87, Num 8, pp 633-640, issn 0008-4212, 8 p.Article

Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscleSMUDER, Ashley J; KAVAZIS, Andreas N; MIN, Kisuk et al.Journal of applied physiology (1985). 2011, Vol 111, Num 4, pp 1190-1198, issn 8750-7587, 9 p.Article

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of EtoposideLAGAS, Jurjen S; LIN FAN; WAGENAAR, Els et al.Clinical cancer research (Print). 2010, Vol 16, Num 1, pp 130-140, issn 1078-0432, 11 p.Article

Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposomeQING CHEN; KROL, Ava; WRIGHT, Alex et al.International journal of hyperthermia. 2008, Vol 24, Num 6, pp 475-482, issn 0265-6736, 8 p.Article

Anserine induced advantage effects on the antitumor activity of doxorubicinSADZUKA, Yasuyuki; SONOBE, Takashi.Food and chemical toxicology. 2007, Vol 45, Num 6, pp 985-989, issn 0278-6915, 5 p.Article

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)LORUSSO, D; DI STEFANO, A; CARONE, V et al.Annals of oncology. 2007, Vol 18, Num 7, pp 1159-1164, issn 0923-7534, 6 p.Article

Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virusTING WU; YAN WANG; YAN YUAN et al.Antiviral research. 2014, Vol 107, pp 95-101, issn 0166-3542, 7 p.Article

Enhancing the Antitumor Activity of Adriamycin and Ionizing RadiationWENQING SUN; KALEN, Amanda L; SMITH, Brian J et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 10, pp 4294-4300, issn 0008-5472, 7 p.Article

Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal DoxorubicinPASTORINO, Fabio; DI PAOLO, Daniela; MARIMPIETRI, Danilo et al.Clinical cancer research (Print). 2008, Vol 14, Num 22, pp 7320-7329, issn 1078-0432, 10 p.Article

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicityREPHAELI, A; WAKS-YONA, S; NUDELMAN, A et al.British journal of cancer. 2007, Vol 96, Num 11, pp 1667-1674, issn 0007-0920, 8 p.Article

Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitorPRESCOTT, Thomas A. K; SADLER, Ian H; KIAPRANIS, Robert et al.Journal of ethnopharmacology. 2007, Vol 109, Num 2, pp 289-294, issn 0378-8741, 6 p.Article

Phase i and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinUNGER, Clemens; HÄRING, Brigitte; MEDINGER, Michael et al.Clinical cancer research. 2007, Vol 13, Num 16, pp 4858-4866, issn 1078-0432, 9 p.Article

Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox CyclingLING LI; QIANGRONG PAN; WEIDONG HAN et al.LING LI; Clinical cancer research. 2007, Vol 13, Num 22, pp 6753-6760, issn 1078-0432, 8 p., 1Article

Endocytic Ark/Prk kinases play a critical role in adriamycin resistance in both yeast and mammalian cellsTAKAHASHI, Tsutomu; FURUCHI, Takemitsu; NAGANUMA, Akira et al.Cancer research (Baltimore). 2006, Vol 66, Num 24, pp 11932-11937, issn 0008-5472, 6 p.Article